Genentech Says Biogen Owes $122M Royalties As Trial Opens

Genentech Inc. told a California federal jury Monday that Biogen MA Inc. owes $122 million in royalties for supplies of Biogen's multiple sclerosis drug that it manufactured before Genentech's patent expired...

Already a subscriber? Click here to view full article